Critics argue that the Controlled Substance Act effectively turned the United States government into enforcers for the pharmaceutical industry. The legislation provided a legal framework that consolidated the industry’s power and restricted competition from alternative medicines and treatments. This monopolistic control not only limited patient choices but also contributed to the rising costs of healthcare and prescription drugs.